Open Beta
TREN
MetriLume
TREN

US marketsBOLT

SEC-sourced researchBeta

BOLT

Bolt Biotherapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001641281
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 21, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 7,690,000.0000 USD; December 2025: 7,695,000.0000 USD7.7M USD0 USD0December 2024December 2025
BOLT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20247,690,000.0000Mar 12, 2026
December 20257,695,000.0000Mar 12, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20257,695,000.0000-33,376,000.0000-39,850,000.000056,748,000.000030,243,000.0000Mar 12, 2026
December 20247,690,000.0000-63,118,000.0000-61,289,000.000099,632,000.000042,434,000.0000Mar 12, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$7.7MDecember 2025Mar 12, 202610-K
Previous period revenueRevenues$7.69MDecember 2024Mar 12, 202610-K
Net incomeNetIncomeLoss-$33.38MDecember 2025Mar 12, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$39.85MDecember 2025Mar 12, 202610-K
Total assetsAssets$56.75MDecember 2025Mar 12, 202610-K
Total liabilitiesLiabilities$30.24MDecember 2025Mar 12, 202610-K

New filings

Explore methodology ↗